Mandate

Vinge is advising Atairos in connection with its $580 million recommended acquisition of the entire issued and to be issued share capital of Ocean Outdoor it does not already own

May 06, 2022 M&A

The transaction will be implemented by way of a statutory merger under BVI law, subject to anti-trust approval in Sweden and other customary approvals and conditions. It is expected that the merger will become effective in June 2022.

Atairos is an independent private company focused on supporting growth-oriented businesses across a wide range of industries. Atairos has approximately $6.5 billion in equity capital and offices in New York City, London and Philadelphia. Ocean Outdoor is a leading operator of digital out-of-home (DOOH) advertising across the United Kingdom, Northern and Continental Europe. Ocean's network of 4,000+ screens covers seven countries and 351 cities with its technological capabilities delivering the most impactful and measurable DOOH brand and advertising experiences. Ocean's portfolio comprises of some of the most iconic locations, such as the Piccadilly Lights and the BFI IMAX. Ocean’s ordinary shares are traded on the Main Market of the London Stock Exchange.

Vinge's team primarily consisted of Sofie Nordgren (Counsel, M&A), Pär Remnelid (Partner, EU / Competition) and Carl Trolle Olson (Associate, M&A).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025